Skip to content

Mirum Pharmaceuticals, Inc. MIRM Common stock, capital shares reserved for future issuance

Common stock, capital shares reserved for future issuance at other companies

Immunovant, Inc. logo
Immunovant, Inc.IMVT

Other financials

Income statement

See full
Revenue$159.9M+43.3%
Operating income-$789.5M-5,100%
Net income-$790.2M-5,284%
EPS (diluted)-$13.43-4,377%

Balance sheet

See full
Cash & equivalents$261.5M+43.5%
Total debt$13.5M+56.4%
Total equity$242.5M+4.0%
Total assets$890.9M+29.1%

Cash flow

See full
Operating cash flow-$228.8M-11,566%
CapEx$664.0K+1,520%
Free cash flow-$229.4M-11,360%

Valuation

See full
Market cap$6.53B+152%
Enterprise value$6.28B+162%
P/S11.5×+4.6×

Profitability

See full
Operating margin-139.8%-168pp
Net margin-140.2%-169pp
FCF margin-30.3%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.1×-1.1×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockCapitalSharesReservedForFutureIssuance.

The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mirum Pharmaceuticals, Inc.'s common stock, capital shares reserved for future issuance.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mirum Pharmaceuticals, Inc.'s common stock, capital shares reserved for future issuance?
Mirum Pharmaceuticals, Inc. (MIRM) reported common stock, capital shares reserved for future issuance of $29.22M in Q1 2026.
How has Mirum Pharmaceuticals, Inc.'s common stock, capital shares reserved for future issuance changed year-over-year?
Mirum Pharmaceuticals, Inc.'s common stock, capital shares reserved for future issuance increased by 7.7% year-over-year, from $27.12M to $29.22M.